Older Adults and Immune Thrombocytopenia: Considerations for the Clinician

References

• Audia S, Mahévas M, Samson M, Godeau B, Bonnotte B. Pathogenesis of immune thrombocytopenia. Autoimmun Rev. 2017;16(6):620–632. doi:10.1016/j.autrev.2017.04.012
   PubMed Web of Science ®Google Scholar
• Moulis G, Palmaro A, Montastruc JL, Godeau B, Lapeyre-Mestre M, Sailler L. Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France. Blood. 2014;124(22):3308–3315. doi:10.1182/blood-2014-05-578336
   PubMed Web of Science ®Google Scholar
• Doobaree IU, Conway K, Miah H, et al. Incidence of adult primary immune thrombocytopenia in England-an update. Eur J Haematol. 2022;109(3):238–249. doi:10.1111/ejh.13803
   PubMed Web of Science ®Google Scholar
• Lucchini E, Fanin R, Cooper N, Zaja F. Management of immune thrombocytopenia in elderly patients. Eur J Intern Med. 2018;58:70–76. doi:10.1016/j.ejim.2018.09.005
   PubMed Web of Science ®Google Scholar
• Mahévas M, Michel M, Godeau B. How we manage immune thrombocytopenia in the elderly. Br J Haematol. 2016;173(6):844–856. doi:10.1111/bjh.14067
   PubMed Web of Science ®Google Scholar
• Terrell DR, Beebe LA, Neas BR, Vesely SK, Segal JB, George JN. Prevalence of primary immune thrombocytopenia in Oklahoma. Am J Hematol. 2012;87(9):848–852. doi:10.1002/ajh.23262
   PubMed Web of Science ®Google Scholar
• Sokal A, de Nadaï T, Maquet J, et al. Primary immune thrombocytopenia in very elderly patients: particularities in presentation and management: results from the prospective CARMEN-France registry. Br J Haematol. 2022;196(5):1262–1270. doi:10.1111/bjh.17935
   PubMed Web of Science ®Google Scholar
• Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3(22):3780–3817. doi:10.1182/bloodadvances.2019000812
   Google Scholar
• McMillan R. Antiplatelet antibodies in chronic immune thrombocytopenia and their role in platelet destruction and defective platelet production. Hematol Oncol Clin North Am. 2009;23(6):1163–1175. doi:10.1016/j.hoc.2009.08.008
   PubMed Web of Science ®Google Scholar
• Vayne C, Guéry EA, Rollin J, Baglo T, Petermann R, Gruel Y. Pathophysiology and diagnosis of drug-induced immune thrombocytopenia. J Clin Med. 2020;9(7):E2212. doi:10.3390/jcm9072212
   PubMed Web of Science ®Google Scholar
• Crickx E, Moulis G, Ebbo M, et al. Safety of anti-SARS-CoV-2 vaccination for patients with immune thrombocytopenia. Br J Haematol. 2021. doi:10.1111/bjh.17813
   PubMedGoogle Scholar
• Fuentes S, Chrétien B, Dolladille C, et al. An updated list of drugs suspected to be associated with immune thrombocytopenia based on the WHO pharmacovigilance database. Blood. 2022;140(8):922–927. doi:10.1182/blood.2022015936
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Giles F, List A, et al. The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer. 2007;109(9):1705–1714. doi:10.1002/cncr.22602
   PubMed Web of Science ®Google Scholar
• Waisbren J, Dinner S, Altman J, et al. Disease characteristics and prognosis of myelodysplastic syndrome presenting with isolated thrombocytopenia. Int J Hematol. 2017;105(1):44–51. doi:10.1007/s12185-016-2081-4
   PubMed Web of Science ®Google Scholar
• Brynes RK, Orazi A, Theodore D, et al. Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenia treated with eltrombopag: data from the EXTEND study. Am J Hematol. 2015;90(7):598–601. doi:10.1002/ajh.24011
   PubMed Web of Science ®Google Scholar
• Rivière É, Viallard JF, Guy A, et al. Intrinsically impaired platelet production in some patients with persistent or chronic immune thrombocytopenia. Br J Haematol. 2015;170(3):408–415. doi:10.1111/bjh.13444
   PubMed Web of Science ®Google Scholar
• Jachiet V, Moulis G, Hadjadj J, et al. Clinical spectrum, outcome and management of immune thrombocytopenia associated with myelodysplastic syndromes and chronic myelomonocytic leukemia. Haematologica. 2021;106(5):1414–1422. doi:10.3324/haematol.2020.272559
   PubMed Web of Science ®Google Scholar
• Comont T, Germain J, Beyne-Rauzy O, Adoue D, Moulis G; Group and the C investigators. Positivity rate of systematic bone marrow smear in patients over 60 years old with newly diagnosed immune thrombocytopenia. Blood Adv. 2020;4(10):2136–2138. doi:10.1182/bloodadvances.2020001654
   PubMed Web of Science ®Google Scholar
• Taparia K, Wall E, Arnold DM, Sun HL. Frequency and utility of bone marrow examination in relapsed/refractory immune thrombocytopenia. J Thromb Haemost. 2022;20(9):2119–2126. doi:10.1111/jth.15802
   PubMed Web of Science ®Google Scholar
• Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829–3866. doi:10.1182/bloodadvances.2019000966
   PubMed Web of Science ®Google Scholar
• Stasi R, Stipa E, Masi M, et al. Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am J Med. 1995;98(5):436–442. doi:10.1016/s0002-9343(99)80342-8
   PubMed Web of Science ®Google Scholar
• Frederiksen H, Schmidt K. The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood. 1999;94(3):909–913. doi:10.1182/blood.V94.3.909.415k02_909_913
   PubMed Web of Science ®Google Scholar
• Vianelli N, Valdrè L, Fiacchini M, et al. Long-term follow-up of idiopathic thrombocytopenic purpura in 310 patients. Haematologica. 2001;86(5):504–509.
   PubMed Web of Science ®Google Scholar
• Cortelazzo S, Finazzi G, Buelli M, Molteni A, Viero P, Barbui T. High risk of severe bleeding in aged patients with chronic idiopathic thrombocytopenic purpura. Blood. 1991;77(1):31–33. doi:10.1182/blood.V77.1.31.31
   PubMed Web of Science ®Google Scholar
• Bourgeois E, Caulier MT, Delarozee C, Brouillard M, Bauters F, Fenaux P. Long-term follow-up of chronic autoimmune thrombocytopenic purpura refractory to splenectomy: a prospective analysis. Br J Haematol. 2003;120(6):1079–1088. doi:10.1046/j.1365-2141.2003.04211.x
   PubMed Web of Science ®Google Scholar
• Bizzoni L, Mazzucconi MG, Gentile M, et al. Idiopathic thrombocytopenic purpura (ITP) in the elderly: clinical course in 178 patients. Eur J Haematol. 2006;76(3):210–216. doi:10.1111/j.1600-0609.2005.00602.x
   PubMed Web of Science ®Google Scholar
• Daou S, Federici L, Zimmer J, Maloisel F, Serraj K, Andrès E. Idiopathic thrombocytopenic purpura in elderly patients: a study of 47 cases from a single reference center. Eur J Intern Med. 2008;19(6):447–451. doi:10.1016/j.ejim.2007.07.006
   PubMed Web of Science ®Google Scholar
• Cohen YC, Djulbegovic B, Shamai-Lubovitz O, Mozes B. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med. 2000;160(11):1630–1638. doi:10.1001/archinte.160.11.1630
   PubMed Web of Science ®Google Scholar
• Michel M, Rauzy OB, Thoraval FR, et al. Characteristics and outcome of immune thrombocytopenia in elderly: results from a single center case-controlled study. Am J Hematol. 2011;86(12):980–984. doi:10.1002/ajh.22170
   PubMed Web of Science ®Google Scholar
• Mithoowani S, Cervi A, Shah N, et al. Management of major bleeds in patients with immune thrombocytopenia. J Thromb Haemost. 2020;18(7):1783–1790. doi:10.1111/jth.14809
   PubMed Web of Science ®Google Scholar
• Zhou H, Fu R, Wang H, et al. Immune thrombocytopenia in the elderly: clinical course in 525 patients from a single center in China. Ann Hematol. 2013;92(1):79–87. doi:10.1007/s00277-012-1567-2
   PubMed Web of Science ®Google Scholar
• Palandri F, Catani L, Auteri G, et al. Understanding how older age drives decision-making and outcome in immune thrombocytopenia. A single centre study on 465 adult patients. Br J Haematol. 2019;184(3):424–430. doi:10.1111/bjh.15668
   PubMed Web of Science ®Google Scholar
• Piel-Julian ML, Mahévas M, Germain J, et al. Risk factors for bleeding, including platelet count threshold, in newly diagnosed immune thrombocytopenia adults. J Thromb Haemost. 2018;16(9):1830–1842. doi:10.1111/jth.14227
   PubMed Web of Science ®Google Scholar
• Swan D, Newland A, Rodeghiero F, Thachil J. Thrombosis in immune thrombocytopenia - current status and future perspectives. Br J Haematol. 2021;194(5):822–834. doi:10.1111/bjh.17390
   PubMed Web of Science ®Google Scholar
• Sarpatwari A, Bennett D, Logie JW, et al. Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom general practice research database. Haematologica. 2010;95(7):1167–1175. doi:10.3324/haematol.2009.018390
   PubMed Web of Science ®Google Scholar
• Doobaree IU, Nandigam R, Bennett D, Newland A, Provan D. Thromboembolism in adults with primary immune thrombocytopenia: a systematic literature review and meta-analysis. Eur J Haematol. 2016;97(4):321–330. doi:10.1111/ejh.12777
   PubMed Web of Science ®Google Scholar
• Ekstrand C, Linder M, Baricault B, et al. Impact of risk factors on the occurrence of arterial thrombosis and venous thromboembolism in adults with primary immune thrombocytopenia – results from two nationwide cohorts. Thromb Res. 2019;178:124–131. doi:10.1016/j.thromres.2019.04.016
   PubMed Web of Science ®Google Scholar
• Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrøm J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost. 2007;5(4):692–699. doi:10.1111/j.1538-7836.2007.02450.x
   PubMed Web of Science ®Google Scholar
• Paran D, Herishanu Y, Elkayam O, Shopin L, Ben-Ami R. Venous and arterial thrombosis following administration of intravenous immunoglobulins. Blood Coagul Fibrinolysis. 2005;16(5):313–318. doi:10.1097/01.mbc.0000172694.85233.a8
   PubMed Web of Science ®Google Scholar
• Thai LH, Mahévas M, Roudot-Thoraval F, et al. Long-term complications of splenectomy in adult immune thrombocytopenia. Medicine. 2016;95(48):e5098. doi:10.1097/MD.0000000000005098
   PubMed Web of Science ®Google Scholar
• Wong RSM, Saleh MN, Khelif A, et al. Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. Blood. 2017;130(23):2527–2536. doi:10.1182/blood-2017-04-748707
   PubMed Web of Science ®Google Scholar
• Kuter DJ, Bussel JB, Newland A, et al. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. Br J Haematol. 2013;161(3):411–423. doi:10.1111/bjh.12260
   PubMed Web of Science ®Google Scholar
• Catalá-López F, Corrales I, de la Fuente-Honrubia C, et al. Risk of thromboembolism with thrombopoietin receptor agonists in adult patients with thrombocytopenia: systematic review and meta-analysis of randomized controlled trials. Med Clin. 2015;145(12):511–519. doi:10.1016/j.medcli.2015.03.014
   PubMed Web of Science ®Google Scholar
• Ghanima W, Cooper N, Rodeghiero F, Godeau B, Bussel JB. Thrombopoietin receptor agonists: ten years later. Haematologica. 2019;104(6):1112–1123. doi:10.3324/haematol.2018.212845
   PubMed Web of Science ®Google Scholar
• Bussel JB, Kuter DJ, Pullarkat V, Lyons RM, Guo M, Nichol JL. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood. 2009;113(10):2161–2171. doi:10.1182/blood-2008-04-150078
   PubMed Web of Science ®Google Scholar
• Lozano ML, Mingot-Castellano ME, Perera MM, et al. A decade of changes in management of immune thrombocytopenia, with special focus on elderly patients. Blood Cells Mol Dis. 2021;86:102505. doi:10.1016/j.bcmd.2020.102505
   PubMed Web of Science ®Google Scholar
• Michel M, Wasser J, Godeau B, et al. Efficacy and safety of the thrombopoietin receptor agonist romiplostim in patients aged ≥ 65 years with immune thrombocytopenia. Ann Hematol. 2015;94(12):1973–1980. doi:10.1007/s00277-015-2485-x
   PubMed Web of Science ®Google Scholar
• Palandri F, Rossi E, Bartoletti D, et al. Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia. Blood. 2021;138(7):571–583. doi:10.1182/blood.2021010735
   PubMed Web of Science ®Google Scholar
• Ruggeri M, Tosetto A, Palandri F, et al. Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment-related risk factors. J Thromb Haemost. 2014;12(8):1266–1273. doi:10.1111/jth.12636
   PubMed Web of Science ®Google Scholar
• Nørgaard M, Jensen AØ, Engebjerg MC, et al. Long-term clinical outcomes of patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study. Blood. 2011;117(13):3514–3520. doi:10.1182/blood-2010-10-312819
   PubMed Web of Science ®Google Scholar
• Portielje JE, Westendorp RG, Kluin-Nelemans HC, Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood. 2001;97(9):2549–2554. doi:10.1182/blood.v97.9.2549
   PubMed Web of Science ®Google Scholar
• Schoonen WM, Kucera G, Coalson J, et al. Epidemiology of immune thrombocytopenic purpura in the general practice research database. Br J Haematol. 2009;145(2):235–244. doi:10.1111/j.1365-2141.2009.07615.x
   PubMed Web of Science ®Google Scholar
• Cooper N, Kruse A, Kruse C, et al. Immune thrombocytopenia (ITP) World Impact Survey (iWISh): patient and physician perceptions of diagnosis, signs and symptoms, and treatment. Am J Hematol. 2021;96(2):188–198. doi:10.1002/ajh.26045
   PubMed Web of Science ®Google Scholar
• Cooper N, Kruse A, Kruse C, et al. Immune thrombocytopenia (ITP) World Impact Survey (I-WISh): impact of ITP on health-related quality of life. Am J Hematol. 2021;96(2):199–207. doi:10.1002/ajh.26036
   PubMed Web of Science ®Google Scholar
• Giordano P, Lassandro G, Valente M, Molinari AC, Ieranò P, Coppola A. Current management of the hemophilic child: a demanding interlocutor. Quality of life and adequate cost-efficacy analysis. Pediatr Hematol Oncol. 2014;31(8):687–702. doi:10.3109/08880018.2014.930768
   PubMed Web of Science ®Google Scholar
• Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115(2):168–186. doi:10.1182/blood-2009-06-225565
   PubMed Web of Science ®Google Scholar
• Matzdorff A, Beer JH. Immune thrombocytopenia patients requiring anticoagulation--maneuvering between scylla and charybdis. Semin Hematol. 2013;50(Suppl 1):S83–S88. doi:10.1053/j.seminhematol.2013.03.020
   PubMedGoogle Scholar
• Godeau B, Bierling P. High-dose dexamethasone as initial treatment for immune thrombocytopenic purpura. N Engl J Med. 2003;349(23):2267–2268;author reply 2267–2268. doi:10.1056/NEJM200312043492318
   Web of Science ®Google Scholar
• Pirunsarn A, Kijrattanakul P, Chamnanchanunt S, Polprasert C, Rojnuckarin P. A randomized multicenter trial comparing low-dose prednisolone versus observation for prevention of recurrences in adult immune thrombocytopenia. Clin Appl Thromb Hemost. 2018;24(6):867–873. doi:10.1177/1076029618764843
   PubMed Web of Science ®Google Scholar
• Wei Y, Ji XB, Wang YW, et al. High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial. Blood. 2016;127(3):296–302;quiz 370. doi:10.1182/blood-2015-07-659656
   PubMed Web of Science ®Google Scholar
• Mithoowani S, Gregory-Miller K, Goy J, et al. High-dose dexamethasone compared with prednisone for previously untreated primary immune thrombocytopenia: a systematic review and meta-analysis. Lancet Haematol. 2016;3(10):e489–e496. doi:10.1016/S2352-3026(16)30109-0
   PubMed Web of Science ®Google Scholar
• Palandri F, Santoro C, Carpenedo M, et al. Management of elderly patients with immune thrombocytopenia: real-world evidence from 451 patients older than 60 years. Thromb Res. 2020;185:88–95. doi:10.1016/j.thromres.2019.11.026
   PubMed Web of Science ®Google Scholar
• Moulis G, Palmaro A, Sailler L, Lapeyre-Mestre M, Latus J. Corticosteroid risk function of severe infection in primary immune thrombocytopenia adults. A nationwide nested case-control study. PLoS One. 2015;10(11):e0142217. doi:10.1371/journal.pone.0142217
   PubMed Web of Science ®Google Scholar
• Bellucci S, Charpak Y, Chastang C, Tobelem G. Low doses v conventional doses of corticoids in immune thrombocytopenic purpura (ITP): results of a randomized clinical trial in 160 children, 223 adults. Blood. 1988;71(4):1165–1169. doi:10.1182/blood.V71.4.1165.1165
   PubMed Web of Science ®Google Scholar
• Godeau B, Chevret S, Varet B, et al. Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial. Lancet. 2002;359(9300):23–29. doi:10.1016/S0140-6736(02)07275-6
   PubMed Web of Science ®Google Scholar
• Khellaf M, Michel M, Schaeffer A, Bierling P, Godeau B. Assessment of a therapeutic strategy for adults with severe autoimmune thrombocytopenic purpura based on a bleeding score rather than platelet count. Haematologica. 2005;90(6):829–832.
   PubMed Web of Science ®Google Scholar
• Godeau B, Caulier MT, Decuypere L, et al. Intravenous immunoglobulin for adults with autoimmune thrombocytopenic purpura: results of a randomized trial comparing 0.5 and 1 g/kg b.w. Br J Haematol. 1999;107(4). doi:10.1046/j.1365-2141.1999.01766.x
   PubMed Web of Science ®Google Scholar
• Caress JB, Kennedy BL, Eickman KD. Safety of intravenous immunoglobulin treatment. Expert Opin Drug Saf. 2010;9(6):971–979. doi:10.1517/14740338.2010.484419
   PubMed Web of Science ®Google Scholar
• Marie I, Maurey G, Hervé F, Hellot MF, Levesque H. Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature. Br J Dermatol. 2006;155(4):714–721. doi:10.1111/j.1365-2133.2006.07390.x
   PubMed Web of Science ®Google Scholar
• Stiehm ER. Adverse effects of human immunoglobulin therapy. Transfus Med Rev. 2013;27(3):171–178. doi:10.1016/j.tmrv.2013.05.004
   PubMed Web of Science ®Google Scholar
• Gaines AR. Acute onset hemoglobinemia and/or hemoglobinuria and sequelae following Rh(o)(D) immune globulin intravenous administration in immune thrombocytopenic purpura patients. Blood. 2000;95(8):2523–2529. doi:10.1182/blood.V95.8.2523
   PubMed Web of Science ®Google Scholar
• Ar G. Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following Rh(0)(D) immune globulin intravenous administration for immune thrombocytopenic purpura. Blood. 2005;106:5. doi:10.1182/blood-2004-11-4303
   Web of Science ®Google Scholar
• Salama A, Kiesewetter H, Kalus U, Movassaghi K, Meyer O. Massive platelet transfusion is a rapidly effective emergency treatment in patients with refractory autoimmune thrombocytopenia. Thromb Haemost. 2008;100(5):762–765. doi:10.1160/TH08-06-0418
   PubMed Web of Science ®Google Scholar
• Spahr JE, Rodgers GM. Treatment of immune-mediated thrombocytopenia purpura with concurrent intravenous immunoglobulin and platelet transfusion: a retrospective review of 40 patients. Am J Hematol. 2008;83(2):122–125. doi:10.1002/ajh.21060
   PubMed Web of Science ®Google Scholar
• Roumier M, Le Burel S, Audia S, et al. High dose romiplostim as a rescue therapy for adults with severe bleeding and refractory immune thrombocytopenia. Am J Hematol. 2021;96(2):E43–E46. doi:10.1002/ajh.26040
   PubMed Web of Science ®Google Scholar
• Zhang J, Liang Y, Ai Y, et al. Eltrombopag versus romiplostim in treatment of children with persistent or chronic immune thrombocytopenia: a systematic review incorporating an indirect-comparison meta-analysis. Sci Rep. 2018;8(1):576. doi:10.1038/s41598-017-19099-8
   PubMedGoogle Scholar
• Kuter DJ, Macahilig C, Grotzinger KM, et al. Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim. Int J Hematol. 2015;101(3):255–263. doi:10.1007/s12185-014-1731-7
   PubMed Web of Science ®Google Scholar
• Al-Samkari H, Jiang D, Gernsheimer T, et al. Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: a multicentre US study. Br J Haematol. 2022;197(3):359–366. doi:10.1111/bjh.18081
   PubMed Web of Science ®Google Scholar
• Bussel JB, Wang X, Lopez A, Eisen M. Case study of remission in adults with immune thrombocytopenia following cessation of treatment with the thrombopoietin mimetic romiplostim. Hematology. 2016;21(4):257–262. doi:10.1179/1607845415Y.0000000041
   PubMed Web of Science ®Google Scholar
• Mahévas M, Fain O, Ebbo M, et al. The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study. Br J Haematol. 2014;165(6):865–869. doi:10.1111/bjh.12888
   PubMed Web of Science ®Google Scholar
• González-López TJ, Sánchez-González B, Jarque I, et al. Use of eltrombopag for patients 65 years old or older with immune thrombocytopenia. Eur J Haematol. 2020;104(3):259–270. doi:10.1111/ejh.13370
   PubMed Web of Science ®Google Scholar
• Ghanima W, Geyer JT, Lee CS, et al. Bone marrow fibrosis in 66 patients with immune thrombocytopenia treated with thrombopoietin-receptor agonists: a single-center, long-term follow-up. Haematologica. 2014;99(5):937–944. doi:10.3324/haematol.2013.098921
   PubMed Web of Science ®Google Scholar
• Rizvi H, Butler T, Calaminici M, et al. United Kingdom immune thrombocytopenia registry: retrospective evaluation of bone marrow fibrosis in adult patients with primary immune thrombocytopenia and correlation with clinical findings. Br J Haematol. 2015;169(4):590–594. doi:10.1111/bjh.13330
   PubMed Web of Science ®Google Scholar
• Godeau B, Porcher R, Fain O, et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter Phase 2 study. Blood. 2008;112(4):999–1004. doi:10.1182/blood-2008-01-131029
   PubMed Web of Science ®Google Scholar
• Auger S, Duny Y, Rossi JF, Quittet P. Rituximab before splenectomy in adults with primary idiopathic thrombocytopenic purpura: a meta-analysis. Br J Haematol. 2012;158(3):386–398. doi:10.1111/j.1365-2141.2012.09169.x
   PubMed Web of Science ®Google Scholar
• Marangon M, Vianelli N, Palandri F, et al. Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long-term response. Eur J Haematol. 2017;98(4):371–377. doi:10.1111/ejh.12839
   PubMed Web of Science ®Google Scholar
• Arnold DM, Dentali F, Crowther MA, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med. 2007;146(1):25–33. doi:10.7326/0003-4819-146-1-200701020-00006
   PubMed Web of Science ®Google Scholar
• Khellaf M, Charles-Nelson A, Fain O, et al. Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients. Blood. 2014;124(22):3228–3236. doi:10.1182/blood-2014-06-582346
   PubMed Web of Science ®Google Scholar
• Deshayes S, Khellaf M, Zarour A, et al. Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: results at 5 years from the French prospective registry ITP-ritux. Am J Hematol. 2019;94(12):1314–1324. doi:10.1002/ajh.25632
   PubMed Web of Science ®Google Scholar
• Patel VL, Mahévas M, Lee SY, et al. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood. 2012;119(25):5989–5995. doi:10.1182/blood-2011-11-393975
   PubMed Web of Science ®Google Scholar
• Hasan A, Michel M, Patel V, et al. Repeated courses of rituximab in chronic ITP: three different regimens. Am J Hematol. 2009;84(10):661–665. doi:10.1002/ajh.21512
   PubMed Web of Science ®Google Scholar
• Zaja F, Vianelli N, Volpetti S, et al. Low-dose rituximab in adult patients with primary immune thrombocytopenia. Eur J Haematol. 2010;85(4):329–334. doi:10.1111/j.1600-0609.2010.01486.x
   PubMed Web of Science ®Google Scholar
• Chugh S, Darvish-Kazem S, Lim W, et al. Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis. Lancet Haematol. 2015;2(2):e75–e81. doi:10.1016/S2352-3026(15)00003-4
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Emery P, Bingham CO, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis. 2013;72(9):1496–1502. doi:10.1136/annrheumdis-2012-201956
   PubMed Web of Science ®Google Scholar
• Cho CH, Hwang WL, Cheng SB, Lee TY, Teng CL. Hepatitis B reactivation induced by Rituximab maintenance therapy for lymphoma. Ann Hematol. 2011;90(1):111–112. doi:10.1007/s00277-010-0962-9
   PubMed Web of Science ®Google Scholar
• Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the research on adverse drug events and reports project. Blood. 2009;113(20):4834–4840. doi:10.1182/blood-2008-10-186999
   PubMed Web of Science ®Google Scholar
• Nazi I, Kelton JG, Larché M, et al. The effect of rituximab on vaccine responses in patients with immune thrombocytopenia. Blood. 2013;122(11):1946–1953. doi:10.1182/blood-2013-04-494096
   PubMed Web of Science ®Google Scholar
• Bussel JB, Lee CS, Seery C, et al. Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration. Haematologica. 2014;99(7):1264–1271. doi:10.3324/haematol.2013.103291
   PubMed Web of Science ®Google Scholar
• Choi PYI, Roncolato F, Badoux X, Ramanathan S, Ho SJ, Chong BH. A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine (TT4). Blood. 2015;126(4):500–503. doi:10.1182/blood-2015-03-631937
   PubMed Web of Science ®Google Scholar
• Zaja F, Baccarani M, Mazza P, et al. Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood. 2010;115(14):2755–2762. doi:10.1182/blood-2009-07-229815
   PubMed Web of Science ®Google Scholar
• Gudbrandsdottir S, Birgens HS, Frederiksen H, et al. Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia. Blood. 2013;121(11):1976–1981. doi:10.1182/blood-2012-09-455691
   PubMed Web of Science ®Google Scholar
• Mahévas M, Azzaoui I, Crickx E, et al. Efficacy, safety and immunological profile of combining rituximab with belimumab for adults with persistent or chronic immune thrombocytopenia: results from a prospective phase 2b trial. Haematologica. 2021;106(9):2449–2457. doi:10.3324/haematol.2020.259481
   PubMed Web of Science ®Google Scholar
• Kojouri K, Vesely SK, Terrell DR, George JN. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood. 2004;104(9):2623–2634. doi:10.1182/blood-2004-03-1168
   PubMed Web of Science ®Google Scholar
• Mageau A, Terriou L, Ebbo M, et al. Splenectomy for primary immune thrombocytopenia revisited in the era of thrombopoietin receptor agonists: new insights for an old treatment. Am J Hematol. 2022;97(1):10–17. doi:10.1002/ajh.26378
   PubMed Web of Science ®Google Scholar
• Gonzalez-Porras JR, Escalante F, Pardal E, et al. Safety and efficacy of splenectomy in over 65-yrs-old patients with immune thrombocytopenia. Eur J Haematol. 2013;91(3):236–241. doi:10.1111/ejh.12146
   PubMed Web of Science ®Google Scholar
• Andrès E, Zimmer J, Noel E, Kaltenbach G, Koumarianou A, Maloisel F. Idiopathic thrombocytopenic purpura: a retrospective analysis in 139 patients of the influence of age on the response to corticosteroids, splenectomy and danazol. Drugs Aging. 2003;20(11):841–846. doi:10.2165/00002512-200320110-00005
   PubMed Web of Science ®Google Scholar
• Kavic SM, Segan RD, Park AE. Laparoscopic splenectomy in the elderly: a morbid procedure? Surg Endosc. 2005;19(12):1561–1564. doi:10.1007/s00464-005-0125-6
   PubMed Web of Science ®Google Scholar
• Park YH, Yi HG, Kim CS, et al. Clinical outcome and predictive factors in the response to splenectomy in elderly patients with primary immune thrombocytopenia: a multicenter retrospective study. Acta Haematol. 2016;135(3):162–171. doi:10.1159/000442703
   PubMed Web of Science ®Google Scholar
• Vianelli N, Palandri F, Polverelli N, et al. Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years. Haematologica. 2013;98(6):875–880. doi:10.3324/haematol.2012.075648
   PubMed Web of Science ®Google Scholar
• Cuker A, Cines DB. Evidence-based mini-review: is indium-labeled autologous platelet scanning predictive of response to splenectomy in patients with chronic immune thrombocytopenia? Hematol Am Soc Hematol Educ Program. 2010;2010(1):385–386. doi:10.1182/asheducation-2010.1.385
   PubMedGoogle Scholar
• Sarpatwari A, Provan D, Erqou S, Sobnack R, David Tai FW, Newland AC. Autologous 111 in-labelled platelet sequestration studies in patients with primary immune thrombocytopenia (ITP) prior to splenectomy: a report from the United Kingdom ITP registry. Br J Haematol. 2010;151(5):477–487. doi:10.1111/j.1365-2141.2010.08377.x
   PubMed Web of Science ®Google Scholar
• Togasaki E, Shimizu N, Nagao Y, et al. Long-term efficacy of partial splenic embolization for the treatment of steroid-resistant chronic immune thrombocytopenia. Ann Hematol. 2018;97(4):655–662. doi:10.1007/s00277-018-3232-x
   PubMed Web of Science ®Google Scholar
• Hou M, Peng J, Shi Y, et al. Mycophenolate mofetil (MMF) for the treatment of steroid-resistant idiopathic thrombocytopenic purpura. Eur J Haematol. 2003;70(6):353–357. doi:10.1034/j.1600-0609.2003.00076.x
   PubMed Web of Science ®Google Scholar
• Taylor A, Neave L, Solanki S, et al. Mycophenolate mofetil therapy for severe immune thrombocytopenia. Br J Haematol. 2015;171(4):625–630. doi:10.1111/bjh.13622
   PubMed Web of Science ®Google Scholar
• Provan D, Moss AJ, Newland AC, Bussel JB. Efficacy of mycophenolate mofetil as single-agent therapy for refractory immune thrombocytopenic purpura. Am J Hematol. 2006;81(1):19–25. doi:10.1002/ajh.20515
   PubMed Web of Science ®Google Scholar
• Bradbury CA, Pell J, Hill Q, et al. Mycophenolate mofetil for first-line treatment of immune thrombocytopenia. N Engl J Med. 2021;385(10):885–895. doi:10.1056/NEJMoa2100596
   PubMed Web of Science ®Google Scholar
• Vesely SK, Perdue JJ, Rizvi MA, Terrell DR, George JN. Management of adult patients with persistent idiopathic thrombocytopenic purpura following splenectomy: a systematic review. Ann Intern Med. 2004;140(2):112–120. doi:10.7326/0003-4819-140-3-200402030-00012
   PubMed Web of Science ®Google Scholar
• Mishra K, Pramanik S, Sandal R, et al. Safety and efficacy of azathioprine in immune thrombocytopenia. Am J Blood Res. 2021;11(3):217–226.
   PubMed Web of Science ®Google Scholar
• Choudhary DR, Naithani R, Mahapatra M, Kumar R, Mishra P, Saxena R. Efficacy of cyclosporine as a single agent therapy in chronic idiopathic thrombocytopenic purpura. Haematologica. 2008;93(10):e61–e62;discussion e63. doi:10.3324/haematol.13481
   PubMedGoogle Scholar
• Kappers-Klunne MC, Van’t Veer MB. Cyclosporin A for the treatment of patients with chronic idiopathic thrombocytopenic purpura refractory to corticosteroids or splenectomy. Br J Haematol. 2001;114(1):121–125. doi:10.1046/j.1365-2141.2001.02893.x
   PubMed Web of Science ®Google Scholar
• Emilia G, Morselli M, Luppi M, et al. Long-term salvage therapy with cyclosporin A in refractory idiopathic thrombocytopenic purpura. Blood. 2002;99(4):1482–1485. doi:10.1182/blood.V99.4.1482
   PubMed Web of Science ®Google Scholar
• Li H, Ji J, Du Y, et al. Sirolimus is effective for primary relapsed/refractory autoimmune cytopenia: a multicenter study. Exp Hematol. 2020;89:87–95. doi:10.1016/j.exphem.2020.08.001
   PubMed Web of Science ®Google Scholar
• Feng Y, Xiao Y, Yan H, et al. Sirolimus as rescue therapy for refractory/relapsed immune thrombocytopenia: results of a single-center, prospective, single-arm study. Front Med. 2020;7:110. doi:10.3389/fmed.2020.00110
   PubMed Web of Science ®Google Scholar
• Li J, Wang Z, Dai L, et al. Effects of rapamycin combined with low dose prednisone in patients with chronic immune thrombocytopenia. Clin Dev Immunol. 2013;2013:548085. doi:10.1155/2013/548085
   PubMedGoogle Scholar
• Verlin M, Laros RK, Penner JA. Treatment of refractory thrombocytopenic purpura with cyclophosphamine. Am J Hematol. 1976;1(1):97–104. doi:10.1002/ajh.2830010111
   PubMed Web of Science ®Google Scholar
• Pizzuto J, Ambriz R. Therapeutic experience on 934 adults with idiopathic thrombocytopenic purpura: multicentric trial of the cooperative Latin American group on hemostasis and thrombosis. Blood. 1984;64(6):1179–1183. doi:10.1182/blood.V64.6.1179.1179
   PubMed Web of Science ®Google Scholar
• Godeau B, Oksenhendler E, Bierling P. Dapsone for autoimmune thrombocytopenic purpura. Am J Hematol. 1993;44(1):70–72. doi:10.1002/ajh.2830440117
   PubMed Web of Science ®Google Scholar
• Godeau B, Durand JM, Roudot-Thoraval F, et al. Dapsone for chronic autoimmune thrombocytopenic purpura: a report of 66 cases. Br J Haematol. 1997;97(2):336–339. doi:10.1046/j.1365-2141.1997.412687.x
   PubMed Web of Science ®Google Scholar
• Zaja F, Marin L, Chiozzotto M, Puglisi S, Volpetti S, Fanin R. Dapsone salvage therapy for adult patients with immune thrombocytopenia relapsed or refractory to steroid and rituximab. Am J Hematol. 2012;87(3):321–323. doi:10.1002/ajh.22266
   PubMed Web of Science ®Google Scholar
• Durand JM, Lefèvre P, Hovette P, Mongin M, Soubeyrand J. Dapsone for idiopathic autoimmune thrombocytopenic purpura in elderly patients. Br J Haematol. 1991;78(3):459–460. doi:10.1111/j.1365-2141.1991.tb04467.x
   PubMed Web of Science ®Google Scholar
• Sauvetre G, MahÉvas M, Limal N, et al. Cutaneous rash and dapsone-induced hypersensitivity syndrome a common manifestation in adult immune thrombocytopenia. Presentation and outcome in 16 cases. Am J Hematol. 2015;90(10):E201–E202. doi:10.1002/ajh.24068
   PubMed Web of Science ®Google Scholar
• Maloisel F, Andrès E, Zimmer J, et al. Danazol therapy in patients with chronic idiopathic thrombocytopenic purpura: long-term results. Am J Med. 2004;116(9):590–594. doi:10.1016/j.amjmed.2003.12.024
   PubMed Web of Science ®Google Scholar
• Liu W, Gu X, Fu R, et al. The effect of danazol in primary immune thrombocytopenia: an analysis of a large cohort from a single center in China. Clin Appl Thromb Hemost. 2016;22(8):727–733. doi:10.1177/1076029615622002
   PubMed Web of Science ®Google Scholar
• Bussel J, Arnold DM, Grossbard E, et al. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two Phase 3, randomized, placebo-controlled trials. Am J Hematol. 2018;93(7):921–930. doi:10.1002/ajh.25125
   PubMed Web of Science ®Google Scholar
• Audia S, Mahévas M, Nivet M, Ouandji S, Ciudad M, Bonnotte B. Immune thrombocytopenia: recent advances in pathogenesis and treatments. Hemasphere. 2021;5(6):e574. doi:10.1097/HS9.0000000000000574
   PubMed Web of Science ®Google Scholar
• Zent CS, Ding W, Reinalda MS, et al. Autoimmune cytopenia in chronic lymphocytic leukemia/small lymphocytic lymphoma: changes in clinical presentation and prognosis. Leuk Lymphoma. 2009;50(8):1261–1268. doi:10.1080/10428190903026492
   PubMed Web of Science ®Google Scholar
• Rogers KA, Woyach JA. Secondary autoimmune cytopenias in chronic lymphocytic leukemia. Seminars in Oncology. 2016;43(2):300–310. doi:10.1053/j.seminoncol.2016.02.011
   PubMed Web of Science ®Google Scholar
• Hauswirth AW, Skrabs C, Schützinger C, et al. Autoimmune thrombocytopenia in non-Hodgkin’s lymphomas. Haematologica. 2008;93(3):447–450. doi:10.3324/haematol.11934
   PubMed Web of Science ®Google Scholar
• Ferretti A, Baldacci E, Miulli E, et al. Thrombopoietin receptor agonists to control immune thrombocytopenia in patients with active lymphoma. Br J Haematol. 2019;186(6):e217–e219. doi:10.1111/bjh.16114
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Giles FJ, Greenberg PL, et al. Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. Blood. 2010;116(17):3163–3170. doi:10.1182/blood-2010-03-274753
   PubMed Web of Science ®Google Scholar
• Giagounidis A, Mufti GJ, Fenaux P, et al. Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia. Cancer. 2014;120(12):1838–1846. doi:10.1002/cncr.28663
   PubMed Web of Science ®Google Scholar
• Fenaux P, Muus P, Kantarjian H, et al. Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy. Br J Haematol. 2017;178(6):906–913. doi:10.1111/bjh.14792
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Fenaux P, Sekeres MA, et al. Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial. Lancet Haematol. 2018;5(3):e117–e126. doi:10.1016/S2352-3026(18)30016-4
   PubMed Web of Science ®Google Scholar
• Mahévas M, Gerfaud-Valentin M, Moulis G, et al. Characteristics, outcome, and response to therapy of multirefractory chronic immune thrombocytopenia. Blood. 2016;128(12):1625–1630. doi:10.1182/blood-2016-03-704734
   PubMed Web of Science ®Google Scholar